Benicar HCT

Benicar HCT is a brand name of hydrochlorothiazide/olmesartan, approved by the FDA in the following formulation(s):

BENICAR HCT (hydrochlorothiazide; olmesartan medoxomil - tablet; oral)

• 
  Manufacturer: DAIICHI SANKYO
  
  Approval date: June 5, 2003
  
  Strength(s): 12.5MG;20MG, 12.5MG;40MG, 25MG;40MG ^[RLD]

Has a generic version of Benicar HCT been approved?

No. There is currently no therapeutically equivalent version of Benicar HCT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Benicar HCT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
  Patent 5,616,599
  Issued: April 1, 1997
  Inventor(s): Yanagisawa; Hiroaki & Fujimoto; Koichi & Amemiya; Yoshiya & Shimoji; Yasuo & Kanazaki; Takuro & Koike; Hiroyuki & Sada; Toshio
  Assignee(s): Sankyo Company, Limited
  Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.
  
  Patent expiration dates:
  
  
  • April 25, 2016
    
    ✓ 
    Patent use: USE AS AN ANTIHYPERTENSIVE AGENT
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • October 25, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical composition
  Patent 6,878,703
  Issued: April 12, 2005
  Inventor(s): Sada; Toshio & Mizuno; Makoto
  Assignee(s): Sankyo Company, Limited
  A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics: The pharmaceutical composition of the present invention has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for preventing or treating hypertension or heart disease.
  
  Patent expiration dates:
  
  
  • November 19, 2021
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • May 19, 2022
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Benicar HCT Consumer Information (Wolters Kluwer)
• Benicar HCT Consumer Information (Cerner Multum)
• Benicar HCT Advanced Consumer Information (Micromedex)
• Hydrochlorothiazide/Olmesartan Consumer Information (Wolters Kluwer)
• Olmesartan/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
• Hydrochlorothiazide and olmesartan Consumer Information (Cerner Multum)
• Olmesartan and hydrochlorothiazide Advanced Consumer Information (Micromedex)